January 1, 2008


IDSA Publishes Updated Guidelines on Aspergillus


New IDSA guidelines on the treatment of Aspergillus have been published in the February 1 issue of Clinical Infectious Diseases, now available online.

The new guidelines replace the previous practice guidelines that were published in 2000. The objective of the new guidelines is to summarize the current evidence for treatment of three different forms of aspergillosis, including invasive, chronic (and saprophytic), and allergic. They also introduce major new anti-fungal agents, including extended spectrum triazoles (such as voriconazole and posaconazole) and echinocandins, a new drug class with anti-Aspergillus activity. 

Similar to the previous practice guidelines, the new set places emphasis on early diagnosis, treatment, and prevention of the different forms of invasive aspergillosis, which include invasive pulmonary, sinus, disseminated and several types of single-organ.

Early detection is vital since aspergillus species have emerged as an important cause of life-threatening infections in patients with compromised immune systems, particularly those with prolonged neutropenia, advanced HIV infection, or those who have undergone allogeneic hematopoietic stem cell or lung transplantation.

As part of its emphasis on the importance of early diagnosis and therapy, the guidelines consider the role of galactomannan and beta-glucan as surrogate markers for early diagnosis, as well as the use of therapeutic drug monitoring (especially for triazoles) and potential for drug toxicity in patients with progressive infection.

Since 2000, new clinical data has been published to support the updated treatment recommendations for Aspergillus, including:

  • A global comparative clinical trial establishing voriconazole as the recommended primary therapy of invasive aspergillosis in most patients
  • A comparison of data establishing the efficacy and safety of liposomal amphotericin B as an alternative agent in some patients
  • Echinocandins being used as salvage therapy
  • Posaconazole prophylaxis being used for prevention of invasive aspergillosis in high-risk patients

In the absence of a well-controlled prospective clinical trial, routine administration of combination therapy is not recommended, but in the setting of salvage therapy, an additional anti-fungal agent might be added to current therapy.  Combination anti-fungal drugs from different classes other than the initial regimen may also be used.  It was also concluded that because of poorer outcomes and increased toxicity, the role of amphotericin B deoxycholate is reduced to resource-limited settings where other agents are not available.

< Previous Article | Next Article >

Adult and Adolescent HIV Treatment Guidelines Updated
IDSA Publishes Updated Guidelines on Aspergillus
CDC Releases Updated Immunization Schedule
Drug Approvals, Shortages, Recalls, Adverse Events
EIN Reports Problems with Vancomycin Levels
In the IDSA Journals
Outbreaks and Bioemergencies
Developing a Research Agenda for HIV and Aging
First Annual IDSA Fellows’ In-Training Exam June 3 and 4
New Resources for State and Regional Societies
CDC Finds Low Rates of Adult Immunization
IDSA Advocacy Update
New Law Requires Free Access to NIH-funded Research
Members on the Move
Welcome, New IDSA Members!
WHO Promotes Community Health Workers for HIV/AIDS Care
Search Back Issues
Forward this Issue
Print-Friendly Version

© Copyright IDSA 2008 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209 info@idsociety.org

Home Page Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA